|
|
|
|
In this double-blind,placebo-controlled trial,we investigated the effect of the catechol-O-methyltransferase inhibitor tolcapone 100 or 200 mg three times daily on activities of daily living and motor function in 298 patients with parkinsonism receiving levodopa but without motor fluctuations.Tolcapone was well tolerated.The principal adverse events were levodopa-related,but there were generally mild or moderate.Diarrhea was the most frequent nondopaminergic adverse event.Tolcapone appears to be beneficial in the treatment of patients with parkinsonism who have not yet developed motor fluctuations. |
|